EU System ‘Not Perfect But Is Fit For Purpose’, Says EMA
EMA Rejects Claims That Industry Fees Distort Evidence
Executive Summary
The European Medicines Agency has rejected claims that industry fees and allegedly flawed methods of evaluating medicines can lead to problematic development and interpretation of evidence.